Revolution Medicines, Inc. - 8-K Filing
Revolution Medicines announced that Steve Kelsey will retire from his role as president of research and development on January 4, 2027, transitioning to a senior advisor position starting July 1, 2026. The company also held its annual stockholder meeting where two Class III directors were elected with vote totals of 127 million for Alexis Borisy (33.7 million withheld) and 157.7 million for Mark Goldsmith (3.2 million withheld). (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $RVMD